Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Fenofibrate Added to Atorvastatin in Mixed Hypercholesterolemia
NCT01956201Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Dec 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mixed hyperlipidemia comparing Atorvastatin + Fenofibrate with Atorvastatin + Placebo (2 arms). Primary endpoint: Mean percent change of Non-HDL Cholesterol at 8 weeks. Status: unknown.
02
Drugs
fenofibrate
03
Conditions
mixed hyperlipidemia
Beyond the preview
Go deeper on NCT01956201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01956201.